Daily Brief China: Unisound AI Technology, Shanghai Haohai Biological Technology-A, Hong Kong Hang Seng Index and more

In today’s briefing:

Unisound: A Chinese Unicorn Focused on AI Powered Voice and Speech Processing Technologies
China Healthcare Weekly (March.3) – TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological
EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades

Unisound: A Chinese Unicorn Focused on AI Powered Voice and Speech Processing Technologies

Founded in 2012, Beijing Yunzhisheng Information Technology Co. (also known as Unisound) is a Chinese company focused on AI powered voice and speech processing technologies.
Unisound provides voice recognition, language processing and big data solutions to home appliances, automobile, healthcare and education companies.
Since the inception of the company, it has raised US$361 million in funding.

The General Office of the State Council issued favorable policy for TCM industry. However, TCM still has to face VBP, therefore Zhangzhou Pientzehuang Pharmaceutical Co. (600436 CH) and Gushengtang are our top picks..
Pfizer is in talks to acquire Seagen in a deal worth over US$30 billion, but we remain conservative about whether this transaction would ultimately bring expected contributions to Pfizer.
Haohai’s business model fails to bring ideal performance. Increasing competition/declining gross margin cast doubts on the outlook of medical aesthetics business. We’re not optimistic about its potential valuation upside.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network